JTCS Concomitant Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Goor, J. M.
Right arrow Articles by Eijsman, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Goor, J. M.
Right arrow Articles by Eijsman, L.
Related Collections
Right arrow Extracorporeal circulation

J Thorac Cardiovasc Surg 2003;126:1101-1106
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Generation of platelet-derived microparticles in patients undergoing cardiac surgery is not affected by complement activation

Jeanette M. van den Goor, MSc, CPa,*, Albert van den Brink, MDa, Rienk Nieuwland, PhDc, Willem van Oeveren, PhDe, Peter M. Rutten, CPa, Robert Tepaske, MDb, Jan G. Tijssen, PhDd, Augueste Sturk, PhDc, Bas A. de Mol, MD, PhDa, León Eijsman, MD, PhDa

a Department of Cardio-thoracic Surgery, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
b Department of Intensive Care,, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
c Department of Clinical Chemistry,, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
e Department ofCardiology, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
e HaemoProbe, Groningen, The Netherlands

Received for publication December 20, 2002; revisions received January 21, 2003; revisions received February 17, 2003; accepted for publication June 16, 2003.

* Address for reprints: Jeanette M. van den Goor, MSc, CP, Department of Cardio-thoracic Surgery, Academic Medical Center of the University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
J.M.vandenGoor{at}AMC.UVA.nl


   Abstract
Top
 Abstract
Materials and methods
 Results
 Discussion
 References
 
OBJECTIVE: The mechanisms causing the presence of platelet-derived microparticles in the circulation are unknown. In vitro platelets release platelet-derived microparticles in response to complement activation. This study evaluates the relationship between complement activation and levels of circulating platelet-derived microparticles in patients undergoing cardiac surgery.

METHODS: Prospectively, 71 patients were included who underwent elective coronary artery bypass grafting with cardiopulmonary bypass. The patients were randomly allocated to one of the 3 groups: uncoated oxygenator, UnModified Surface (n = 25) or oxygenator coated with either BioPassive Surface (n = 25) or BioActive Surface (n = 21). Platelet-derived microparticles and terminal complement complexes were determined before bypass and after induction of anesthesia, 15 minutes after the start of cardiopulmonary bypass, at the end of cardiopulmonary bypass, and 30 minutes after administration of protamine sulfate.

RESULTS: Demographic and cardiopulmonary bypass data were similar for the 3 groups. At the end of cardiopulmonary bypass, platelet-derived microparticle numbers were decreased in all 3 groups. No significant differences were observed among the groups at any sampling point. At the end of cardiopulmonary bypass, terminal complement complex concentrations were increased in all groups (P < .001), and significant differences among the groups were present (P = .002).

CONCLUSIONS: Despite significant complement activation, no increase in numbers of circulating platelet-derived microparticles was found in the systemic blood of patients undergoing cardiac surgery with cardiopulmonary bypass. Thus complement activation in vivo does not necessarily affect generation of platelet-derived microparticles.

On activation and during apoptosis, platelets and other cells bud off small parts of their plasma membrane, the so-called microparticles. Extensive in vitro studies have been reported on platelet-derived microparticles (PMPs).1,2 When platelets are stimulated in vitro with agonists, such as a combination of {alpha}-thrombin and collagen, the complement complex C5b-9, or the Ca2+ ionophore A23187, they release large numbers of PMPs.1,3,4 PMPs possess platelet factor 3 activity; that is, they facilitate coagulation through exposure of negatively charged phospholipids, thereby providing binding sites for activated coagulation factors V (factor Va), VIIIa, IXa, and XIa1,2,5,6 and enabling the formation of tenase and prothrombinase complexes.1,2,7

Increased numbers of PMPs have been reported in the circulation of patients with diabetes,8,9 patients undergoing cardiopulmonary bypass (CPB),10,11 and patients with acute coronary ischemia,12 heparin-induced thrombocytopenia,13 myocardial infarction,14 uremia,15 idiopathic thrombocytopenic purpura,16 disseminated intravascular coagulation,17 plasmapheresis,18 or meningococcal septic shock,19 which are all diseases that have been associated with a thromboembolic tendency. Increased numbers of PMPs have been found also in the pericardial fluid of patients undergoing surgical intervention with CPB.20

Despite the widespread presence of PMPs in the circulation, however, the mechanisms causing their release in vivo are still unknown. Complement activation is markedly increased during CPB, whereas coatings are known to reduce complement activation. Generation of PMPs induced by complement activation was anticipated. Therefore in the present study the relationship between in vivo complement activation and the concentrations of circulating PMPs was evaluated in patients undergoing cardiac surgery with CPB with noncoated oxygenators and coated oxygenators.


   Materials and methods
Top
 Abstract
 Materials and methods
Results
 Discussion
 References
 
Patients
On approval of the Medical Ethics Committee of the Academic Medical Center and obtainment of signed informed consent, we prospectively included 71 patients who underwent elective coronary artery bypass grafting with CBP. Inclusion criteria were age 21 to 75 years, elective coronary artery bypass surgery, ejection fraction of greater than 30%, body surface area of greater than 1.66 m2, and a preoperative hemoglobin value of greater than 7.5 mmol/L. Exclusion criteria were combined valve surgery or aneurysmectomy, redo operations, insulin-dependent diabetes mellitus, creatinine plasma level of greater than 300 µmol/L, preoperative intra-aortic balloon pumping, preoperative use of nonsteroidal anti-inflammatory drugs, preoperative use of warfarin, preoperative immunosuppressive therapy of greater than 24 hours' duration, allergic reactions, and chronic obstructive pulmonary disease. The patients were randomly allocated to one of 3 groups (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Demographic and CPB data

 
CPB
All extracorporeal bypass circuits consisted of a hollow-fiber oxygenator (Affinity; Medtronic, Minneapolis, Minn). The oxygenator was uncoated (ie, without surface modification, UnModified Surface [UMS; n = 25]) or coated with either BioPassive Surface (BPS; n = 25; Trillium, Medtronic) or BioActive Surface (BAS; n = 21; Carmeda, Medtronic). The additional noncoated components of the extracorporeal circuit were identical for all patients and included a soft-shell venous reservoir, 2 additional reservoirs, an arterial line filter, a tubing system (Medtronic), and a roller pump as an arterial blood pump (3M Sarns, Ann Arbor, Mich). One of the additional reservoirs was used to collect the shed blood, which was processed by a cell saver before being returned into the systemic circulation after termination of the bypass procedure. The other reservoir was used to collect left vent (systemic) blood, which was returned into the systemic circulation through the soft-shell venous reservoir during the bypass procedure. The extracorporeal system was primed with 500 mL of Ringer lactate solution, 1 L of Haemaccell (Behring, Malburg, Germany), 100 mL of mannitol 20% (wt/vol), 50 mL of sodium bicarbonate 8.4% (wt/vol), and 200 mL of aprotinin (2 x 106 KIU Trasylol; Bayer, Leverkusen, Germany). Magnesium sulfate, 4 mmol/10 kg (ie, 24 >= x <= 32 mmol) and 10,000 IU of bovine heparin (Leo Pharmaceutical Products, Weesp, The Netherlands) were added to the priming solution. The total priming volume was 1.85 L. All patients received 300 IU/kg heparin (Leo Pharmaceutical Products) before cannulation of the aorta. CPB was initiated when the activated clotting time was 480 seconds or greater. During CPB, the activated clotting time was maintained at greater than 480 seconds by means of administration of additional heparin when required. Moderate hypothermia (30°C-34°C) was used for all patients. Myocardial protection was achieved by using cold (4°C-8°C) crystalloid cardioplegia solution (St Thomas). Shed blood in the surgical field was processed with a cell saver (HaemoLite 2 plus; Haemonetics Corp, Braintree, Mass). Processed blood was returned into the systemic circulation of the patients immediately after CPB. After weaning from CPB and decannulation, heparin was neutralized with protamine sulfate at a 1:1 ratio.

Collection of blood samples
Arterial blood samples were obtained before induction of anesthesia, 15 minutes after the start of CPB, at the termination of CPB, and 30 minutes after protamine administration. For comparison between plasma samples, PMP numbers, platelet counts, and terminal complement complex (TCC) concentrations were corrected for hemodilution by hemoglobin concentration.

Cell count
Blood samples for hemoglobin and platelet counts were collected in 5-mL glass vacutainer tubes containing ethylenediamine tetra-acetic acid (Becton Dickinson, San Jose, Calif) and analyzed on a Celldyn 4000 (Abbot, Mijdrecht, The Netherlands).

TCCs
Arterial blood (2 mL) was anticoagulated with 10 mmol/L ethylenediamine tetra-acetic acid. Cell-free plasma aliquots (1 mL) were prepared by means of centrifugation (11 minutes at 1100g and 4°C) and stored at -80°C until use. TCC measures the TCC bound to the S-protein, representing the soluble nonlytic form of TCC. TCC was determined by means of enzyme-linked immunoassay (Quidel, San Diego, Calif).

PMPs
Arterial blood (4.5 mL) was collected into 3.2% trisodium citrate (Becton Dickinson). Blood cells were removed by means of centrifugation for 20 minutes at 1550g and room temperature, and plasma aliquots (250 µL) were snap-frozen in liquid nitrogen and stored at -80°C until use. After thawing plasma aliquots on melting ice, plasma was centrifuged for 30 minutes (17,570g and 20°C) to pellet the microparticles, as described previously.19-22 After removal of 225 µL of (MP-free) plasma, the 25-µmL microparticle-enriched plasma was diluted with 225 µmL of phosphate-buffered saline (PBS; 154 mmol/L NaCl and 1.4 mmol/L phosphate, pH 7.4) containing 10.9 mmol/L trisodium citrate. Microparticles were resuspended and centrifuged (30 minutes at 17,570g and 20°C). Again, 225 µL of the supernatant was removed, and microparticles were resuspended in the remaining 25 µL and diluted 4-fold with PBS/citrate buffer, of which 5 µL was used per flow cytometric determination.

Flow cytometric analysis
Microparticle samples were analyzed in a FACSCalibur flow cytometer with CellQuest software (Becton Dickinson). PMPs were identified on forward scatter, side scatter, and binding of both phycoerythrin-labeled annexin V (PharMingen, San Jose, Calif) and fluorescein isothiocyanate–labeled anti-CD61 (glycoprotein IIIA; clone Y2/51, IgG1; Dako A/S, Glostrup, Denmark) to distinguish PMPs from events caused by noise. To identify annexin V–positive microparticles, a fluorescence threshold was placed in a microparticle sample prepared without addition of calcium to correct for autofluorescence. To identify CD61-positive events, microparticles were incubated with a similar concentration of isotype-matched control antibody (fluorescein isothiocyanate–labeled IgG1; Becton Dickinson) to set the fluorescence threshold. Microparticles (5 µL) were diluted in 35 µL of PBS containing 2.5 mmol/L CaCl2 (pH 7.4) and 5 µL of 500-fold prediluted normal mouse serum (Central Laboratory of the Netherlands Red Cross Bloodtransfusion Service, Amsterdam, The Netherlands). After incubation for 15 minutes at room temperature, annexin V (5 µL) plus anti-CD61 (5 µL) or IgG1 control antibody was added. The mixtures were incubated in the dark (15 minutes at room temperature). Subsequently, 200 µL of PBS/calcium buffer was added, and the suspensions were centrifuged (30 minutes at 17,570g and 20°C). Finally, 200 µL of (MP-free) suspension was removed. The microparticles were diluted in 300 µL of PBS/calcium buffer before flow cytometry, and all samples were analyzed for 1 minute. To estimate the number of PMPs per liter of plasma, the number of events (N) found in the upper right (marker and annexin V positive) quadrant of the flow cytometric analysis (FL1 vs FL2) was used in the following formula: Number/L = N x [100/5] x [355/150] x [106/250].

Statistics
Data were analyzed by using SPSS, release 11.0 (SPSS, Chicago, Ill). Demographic and CPB data are reported as means with SDs. Outcome data (PMPs, platelets, and TCCs) were corrected for hemodilution (hemoglobin) and are presented as medians with interquartile ranges. For all outcome variables, statistical analyses were performed on the change of that variable relative to the baseline value (t = 0) per patient. Statistical significance (P < .05, 2-sided) is indicated. The sample size was chosen on the basis of preliminary observations, indicating that approximately 25 patients per group would be sufficient to achieve statistically significant differences in blood activation between coated and noncoated oxygenators. Comparisons over time within treatment groups were made by applying the Wilcoxon signed-rank test to the (paired) observations at baseline and at the end of CPB. Comparisons between (treatment) groups were made by applying the Kruskal-Wallis test to the change between the end of CPB and baseline. The observations at 15 minutes after the start of CPB and at 30 minutes after protamine sulfate are presented for descriptive purposes.


   Results
Top
 Abstract
 Materials and methods
 Results
Discussion
 References
 
Clinical results
The coating groups (UMS, BPS, and BAS) were compared for preoperative parameters, including body surface area, age, sex, hemoglobin value, platelet count, and surgical data (CPB time and aortic crossclamping time). No significant differences were found among the groups for any of the variables tested (Table 1). There were no differences among the groups in hemoglobin concentrations and platelet counts at any sampling time. Hemodilution was similar in the 3 coating groups: the decreases in hemoglobin concentrations and platelet counts after the start of the CPB procedure were most likely due to hemodilution of the systemic patient blood by the priming volume of the extracorporeal circuit and administration of the cardioplegia solution for myocardial protection. In addition, in all 3 coating groups, a similar decrease in platelet count was observed after administration of protamine sulfate.

PMPs and platelet counts during CPB
The numbers of PMPs at baseline were similar among the 3 coating groups (Figure 1, A). Fifteen minutes after the start of CPB, the PMP numbers decreased in all 3 groups, despite correction for hemodilution. During CPB, the PMP numbers slightly recovered, but at the end of bypass, they were still less than before the start of CPB. At the end of bypass, there was a significant decrease of PMPs in the UMS group (P < .001) and the BPS group (P = .028) when compared with baseline values. After administration of protamine sulfate, PMP numbers again slightly decreased in all groups. Significant differences were not observed among the groups at any sampling point.



View larger version (23K):
[in this window]
[in a new window]
  		Figure 1. Systemic concentrations of PMPs and platelet counts in patients undergoing CPB. Concentrations of PMPs and platelet counts before bypass and after induction of anesthesia (baseline value; pre), 15 minutes after the start of bypass (15'CPB), at the end of bypass and after release of the aortic crossclamp (end CPB), and 30 minutes after administration of protamine sulfate (30'prot) are shown. The measurements were made in 25 patients treated with an uncoated oxygenator (ie, without Surface Modification, UMS group, open bars), 25 patients treated with an oxygenator coated with a BioPassive Surface (BPS group, shaded bars), and 21 patients treated with an oxygenator coated with a BioActive Surface (BAS group, striped bars). PMP concentrations (A) and platelet counts (B) were determined as described in the "Methods" section. No significant differences were present among the 3 oxygenator groups. Medians and interquartile ranges are presented.

 
In contrast to PMP numbers, platelet counts significantly increased during CPB when corrected for hemodilution (Figure 1, B; end of CPB: UMS group, P = 0.004; BPS group, P < .001, and BAS group, P = .003).

Complement activation during CPB
Before CPB, complement activation was not detectable or hardly detectable (Figure 2). Fifteen minutes after the start of CPB, plasma concentrations of TCCs increased in all 3 coating groups, indicating complement activation. TCC concentrations further increased during CPB and remained high after protamine sulfate administration. At the end of CPB, TCC concentrations were significantly increased in all 3 groups (P < .001) when compared with baseline values. At the end of CPB, significant differences among the coating groups were present (P = .002). At the other sample times, no significant differences among the coating groups were found.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 2. Concentrations of systemic TCCs in patients undergoing CPB. TCC concentrations before bypass and after induction of anesthesia (baseline value, pre), 15 minutes after the start of bypass (15'CPB), at the end of bypass and after release of the aortic crossclamp (end CPB), and 30 minutes after administration of protamine sulfate (30'prot) are shown. The measurements were made in 25 patients treated with an uncoated oxygenator (ie, without Surface Modification (UMS group, open bars), 25 patients treated with an oxygenator coated with a BioPassive Surface (BPS group, shaded bars), and 21 patients treated with an oxygenator coated with a BioActive Surface (BAS group, striped bars) and performed as described in the "Methods" section. Medians and interquartile ranges are presented.

 

   Discussion
Top
 Abstract
 Materials and methods
 Results
 Discussion
References
 
This study shows that despite considerable activation of the complement system in vivo, circulating PMP numbers did not increase. These results were not anticipated because earlier in vitro studies clearly showed that complement activation triggers the release of PMPs.1,4,23-25 Our present data, however, suggest that other mechanisms must be involved in the release of microparticles in vivo. On the other hand, we cannot exclude that complement activation might contribute to microparticle release in other patient populations or that it might affect the release of microparticles in concert with other stimuli.

Earlier studies reported that CPB triggers the formation of PMPs both in vitro26 and in vivo.10,11 In contrast, we found an intraoperative decrease in PMP numbers. Most likely, this lack of increase is due to the many relatively recent improvements of the extracorporeal circuits.27-29 Alternatively, in the present study the pericardial blood was not reinfused during the bypass procedure but rather afterward. Because pericardial blood contains relatively high numbers of cell-derived microparticles itself and is highly activated with regard to fibrinolysis and coagulation, one could hypothesize that by not returning this blood into the systemic circulation during bypass, one of the triggers for (systemic) blood activation has been eliminated. The same holds for platelet activation. Whereas earlier studies reported extensive platelet activation during CPB, more recent studies showed less platelet activation.27,30 For instance, Kestin and colleagues30 reported that platelets from the systemic circulation of patients undergoing CPB showed normal reactivity in vitro, had no loss of surface glycoprotein complexes Ib-IX and IIb-IIIa, and had hardly degranulated.

In contrast, pericardial blood contains relatively high numbers of PMPs and erythrocyte-derived microparticles.20,27 Whether local complement activation (ie, in this wound blood) contributes to the release of PMPs cannot be excluded.

In the present study this shed blood was processed by a cell saver before being returned to the systemic circulation after the bypass procedure had been terminated. This treatment excludes the possibility that systemic blood activation during the bypass procedure is caused by reinfusion of the processed shed blood. On the other hand, we cannot exclude that this reinfusion contributes to blood activation after bypass.

Taken together, although the release of microparticles in vitro from platelets is initiated by complement activation, we found no evidence for a relationship between complement activation and the concentrations of PMPs in systemic blood from patients undergoing CPB. We conclude that complement activation in vivo does not importantly affect the generation of PMPs.


   Acknowledgments
 
We thank all our colleagues who supported this study and in particular M. C. L. Schaap, R. Baak-Pablo, C. Hau, and H. Everts for excellent technical assistance.


   Footnotes
 
Supported by Medtronic, Minneapolis, Minn.


   References
Top
 Abstract
 Materials and methods
 Results
 Discussion
 References
 

  1. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 1988;263:18205–18212[Abstract/Free Full Text]
  2. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem. 1989;264:17049–17057[Abstract/Free Full Text]
  3. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 1991;77:2641–2648[Abstract/Free Full Text]
  4. Wiedmer T, Sims PJ. Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood. 1991;78:2880–2886[Abstract/Free Full Text]
  5. Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991;266:17261–17268[Abstract/Free Full Text]
  6. Hoffman M, Monroe DM, Roberts HR. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost. 1992;68:74–78[Medline]
  7. Holme PA, Brosstad F, Solum NO. Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood Coagul Fibrinolysis. 1995;6:302–310[Medline]
  8. Nomura S, Shouzu A, Omoto S, Hayakawa T, Kagawa H, Nishikawa M, et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost. 1998;80:388–392[Medline]
  9. Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995;116:235–240[Medline]
  10. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood. 1990;75:128–138[Abstract/Free Full Text]
  11. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest. 1986;78:340–348
  12. Katopodis JN, Kolodny L, Jy W, Horstman LL, De Marchena EJ, Tao JG, et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol. 1997;54:95–101[Medline]
  13. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691–3699[Abstract/Free Full Text]
  14. Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res. 1993;72:295–304[Medline]
  15. Nomura S, Shouzu A, Nishikawa M, Kokawa T, Yasunaga K. Significance of platelet-derived microparticles in uremia. Nephron. 1993;63:485[Medline]
  16. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119:334–345[Medline]
  17. Holme PA, Solum NO, Brosstad F. Clinical significance of platelet-derived microvessels: demonstration of their presence in patients suffering from disseminated intravascular coagulation (DIC). Thromb Haemost. 1993;69:6
  18. Wun T, Paglieroni T, Holland P. Prolonged circulation of activated platelets following plasmapheresis. J Clin Apheresis. 1994;9:10–16[Medline]
  19. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000;95:930–935[Abstract/Free Full Text]
  20. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 1997;96:3534–3541[Abstract/Free Full Text]
  21. Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost. 2001;85:810–820[Medline]
  22. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–646[Medline]
  23. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost. 1999;82:794–800[Medline]
  24. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809–3814[Abstract/Free Full Text]
  25. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999;30:111–142[Medline]
  26. Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med. 1995;125:276–287[Medline]
  27. Maquelin KN, Berckmans RJ, Nieuwland R, Schaap MC, ten Have K, Eijsman L, et al. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998;115:1160–1165[Abstract/Free Full Text]
  28. Aldea GS, Soltow LO, Chandler WL, Triggs CM, Vocelka CR, Crockett GI, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg. 2002;123:742–755[Abstract/Free Full Text]
  29. De Somer F, Van Belleghem Y, Caes F, Francois K, Van Overbeke H, Arnout J, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2002;123:951–958[Abstract/Free Full Text]
  30. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, et al. The platelet function defect of cardiopulmonary bypass. Blood. 1993;82:107–117[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 FASEB J.Home page
N. Pacienza, R. G. Pozner, G. A. Bianco, L. P. D'Atri, D. O. Croci, S. Negrotto, E. Malaver, R. M. Gomez, G. A. Rabinovich, and M. Schattner
The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation
FASEB J, April 1, 2008; 22(4): 1113 - 1123.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
J. M van den Goor, W. van Oeveren, P. M Rutten, J. G Tijssen, and L. Eijsman
Adhesion of thrombotic components to the surface of a clinically used oxygenator is not affected by Trillium coating
Perfusion, May 1, 2006; 21(3): 165 - 172.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van den Goor, J. M.
Right arrow Articles by Eijsman, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van den Goor, J. M.
Right arrow Articles by Eijsman, L.
Related Collections
Right arrow Extracorporeal circulation

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS